Isaac Ho is CIO of MiRXES where he oversees corporate development and investor relations as well as builds strategic partnerships with key health care players and financial institutions. Prior to MiRXES, Isaac founded Singapore Health, and subsequently VentureCraft Group, a Singapore government accredited co-investment partner and incubator in the health care and biomedical sciences sector. He is a veteran in entrepreneurship, investment and business management. Under his leadership, Venturecraft Group was appointed as an accelerator under SPRING Singapore’s Sector Specific Accelerator Programme for Biomedical Sciences. Isaac graduated from Deakin University with a Bachelor’s Degree in Commerce (Marketing and Management).
MiRXES is a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered cancer early detection tests.
MiRXES’ story began in early 2000 when the founders pioneered a highly sensitive, specific and robust detection technology for MicroRNA (miRNA), the smallest genetic material ever found in human and other living organisms. Realizing the potential of miRNA-based clinical applications in solving unmet needs in cancer, cardiovascular, metabolic and infectious diseases, MiRXES decided to bring its technology from laboratory to clinic. In 2014, MiRXES spun off from A*STAR to commercialize the technology, develop accurate multi-cancer early detection solutions and make them readily available and accessible.
MiRXES believes that the future of health care will shift from treating the sick to preventive health care. The company’s focus on science and innovation will continue as it commits to changing lives and delivering preventive health care solutions to all.